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Abstract
Background: CCL16 is a chemokine predominantly expressed in the liver, but is also found in the blood and brain, and
is known to play important roles in immune response and angiogenesis. Little is known about the gene’s regulation.
Methods: Here, we test for potential causal SNPs that affect CCL16 protein levels in both blood plasma and cerebrospinal fluid
in a genome-wide association study across two datasets. We then use METAL to performed meta-analyses with a significance
threshold of p< 5x10−8. We removed SNPs where the direction of the effect was different between the two datasets.
Results:We identify 10 SNPs associated with increased CCL16 protein levels in both biological fluids.
Conclusions: Our results will help understand CCL16’s regulation, allowing researchers to better understand the gene’s effects
on human health.
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Background
Chemokines are specialized cytokines (cell-signaling
proteins) that induce chemotaxis in proximal cells.
The CC subfamily is primarily a chemoattractant to
monocytes and lymphocytes [1], demonstrating their
role in immune response. Chemokines are highly con-
served across species, suggesting their roles are essential
to viable offspring [2]. They have been implicated specific-
ally in brain health, including neuronal migration during
development and even neuronal death [2, 3], which has
important implication on brain health throughout life and
could have important implications in neurodegenerative
diseases. CCL16 is part of the CC chemokine subfamily
and is predominantly expressed in the liver [4]. The
CCL16 protein is also known to be present and active in
the brain and blood [3, 5].
CCL16 is located on the q arm of chromosome 17
amongst a cluster of other chemokines and is known to
play a role in angiogenesis [5]. While the CCL16 protein
is known to be heavily active in the liver, little is known
about its overall regulation in the brain and blood.
To date, most research regarding CCL16 is limited to
its expression in the liver and its role in chemotaxis,
generally. Little is known about CCL16 gene regulation
and the protein’s role across all tissues. It is clearly in-
volved in immune response, as one of its primary func-
tions is to attract lymphocytes and monocytes [1],
making CCL16 a potentially critical protein throughout
the body. It is also unclear how CCL16 protein levels
across blood plasma and CSF are regulated.
Here, we measure CCL16 protein levels in cerebrospinal
fluid (CSF) and blood plasma, and perform a genome-wide
association analysis to identify SNPs that are associated
with CCL16 levels in both CSF and blood plasma. These
findings will help clarify CCL16 regulatory mechanisms and
their effects on human development and health.
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Methods
Subjects and data description
Exactly 246 and 240 CSF and blood plasma samples, re-
spectively, were used in this study from participants in the
Knight-Alzheimer’s disease Research Center at Washing-
ton University School of Medicine (Knight ADRC) and
297 and 347 CSF and blood plasma samples, respectively,
were used from the Alzheimer’s Disease Neuroimaging
Initiative (ADNI). From the Knight ADRC samples, ap-
proximately 93 % of the samples were controls, and 7 %
were Alzheimer’s disease cases, and from the ADNI sam-
ples, approximately 85 % were controls, and 15 % were
AD cases. We measured levels for CCL16 in each sample
using the Human DiscoveryMAP Panel v1.0 and a Lumi-
nex 100 platform [6]. All samples were genotyped using
the Illumina 610 or the Omniexpress chip. The Knight
ADRC samples and associated collection methods were
previously described [7, 8]. We collected the ADNI sam-
ples from the ADNI database (adni.loni.usc.edu), which
were part of the ADNI biomarker study [9]. All samples
are of European descent.
SNP imputation
The SNPs were imputed as previously described [6].
Briefly, data from the 1000 Genomes Project (June 2012
release) were used to impute SNPs using Beagle. Im-
puted SNPs with the following criteria were removed:
(1) an r2 of 0.3 or lower, (2) a minor allele frequency
(MAF) lower than 0.05 (3) out of Hardy-Weinberg equi-
librium (p < 1 × 10 − 6), (4) a call rate lower than 95 %,
or (5) a Gprobs score lower than 0.90. Exactly 5,815,690
SNPs passed the QC process.
Data cleaning and analysis
We excluded SNPs that exceeded thresholds for Hardy-
Weinberg Equilibrium [10, 11] (−−hwe 0.00001), missing
genotype rate (−−geno 0.05), and minor allele frequency
(−−maf 0.01) for each data set, using PLINK version 1.07
[12], to perform genotype quality control. We then ex-
cluded individuals with a missing genotyping rate greater
than 2 % (−−mind 0.02), leaving 246 individuals from
Knight ADRC and 282 samples from ADNI after clean-
ing. Remaining Knight ADRC and ADNI samples con-
sisted of 40 and 61 % males, respectively. The average
age for ADNI samples was 76 years, ranging from 58 to
91 years, and the average age for Knight ADRC samples
was 73, ranging from 49 to 91.
After data cleaning, we tested for an association be-
tween each remaining SNP and CCL16 CSF levels within
each dataset, adjusting for age, gender, and the first two
principal components generated by EigenSoft [13, 14].
We then performed a meta-analysis across both data
sets, accounting for sample size, p-values, and direction
of effect using the default METAL [15] settings. We
retained all SNPs that had a genome-wide significant
meta-analysis p-value less than 5×10−8 and that had the
same direction of effect in both datasets. We then tested
associations between each SNP and CCL16 plasma levels
following the same protocol and kept only those SNPs
that were significantly associated with both CSF and
plasma CCL16 levels.
To assess known functional effects and identify SNPs
that are biologically likely to modify gene expression or
function, we searched all significant SNPs in the NHGRI
catalog of published genome-wide association studies [16]
(downloaded July, 2015) for known disease associations,
collected RegulomeDB annotations (accessed September,
2015) [17], and collected functional annotations from
wANNOVAR [18, 19].
We performed a conditional analysis for all included
SNPs that were in or near a given region to test whether
there is one or multiple independent effects in the re-
gion [20]. Conditional analysis is a follow-up method
used to test if there are secondary association signals
within a region by retesting each SNP while including
the top SNP as a covariate. We chose the most signifi-
cant SNP in the region to use as a covariate in the con-
ditional analysis.
Results
We identified 34 and 25 SNPs significantly associated
with CCL16 protein levels in CSF and plasma, respect-
ively (Additional file 1 and Additional file 2). Of these,
10 SNPs were significantly associated with increased
CCL16 protein levels in both CSF and plasma, based on
the meta-analyses, all of which are in or near the CCL16
gene (Table 1). The genomic inflation factor was 1.0 (q-q
plots can be found in Additional file 3 and Additional
file 4). None of the 10 SNPs have been reported to show
association with disease in the NHGRI GWAS catalog.
Two SNPs are located in the 3’ untranslated region
(UTR), 4 are intronic, 1 is downstream, and 3 are inter-
genic (Table 1). SNPs are identified as “downstream” if
they are within 500 nucleotides of the 3’ end of a gene,
according to the National Center for Biotechnology In-
formation’s (NCBI) SNP FAQ Archive [21]. Minor allele
frequencies (MAF) for the ten SNPs ranged from 0.06 to
0.14 and RegulomeDB scores ranged from ‘1f ’ to ‘6’, with
three SNPs having no known regulation data, according
to RegulomeDB.
All ten SNPs associated with both CSF and plasma
CCL16 protein levels are in high linkage disequilibrium,
suggesting there is likely one association signal in the re-
gion (Figs. 1 and 2). The conditional analysis further
supports a single signal as the p-values are no longer
genome-wide significant when including the most sig-
nificant SNP, rs80329614, as a covariate. SNP
rs80329614 is the SNP identified as being “downstream”
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of CCL16 (Table 1, Figs. 1 and 2) and has a RegulomeDB
score of ‘3a’.
SNP rs11080369 is an intronic SNP with a RegulomeDB
score of ‘1f ’ and was previously demonstrated to be within
an expression quantitative trait locus (eQTL) that specific-
ally modifies CCL16 gene expression [22]. The remaining
8 SNPs do not have known regulatory associations or
functions, according to RegulomeDB, but 5 of the 8 are lo-
cated in genic regions, such as UTRs and introns.
Discussion
We identified exactly 10 SNPs associated with increased
CCL16 protein levels in both CSF and blood plasma, all
of which were located in or around the CCL16 gene and
based on the conditional analysis, all representing on
single signal. The SNP most strongly associated with
CCL16 protein levels was rs80329614, which was identi-
fied as being “downstream” (within 500 nucleotides
downstream) of CCL16 with a RegulomeDB score of
“3a”. RegulomeDB scores range from “1a” to “6” where
lower scores indicate stronger evidence that the SNP af-
fects gene regulation based on both empirical data, such
as ChIP-seq, and whether the SNP is within a known
transcription factor binding motif. A score of “3a” indi-
cates minimal evidence that a SNP is involved in gene
regulations, but RegulomeDB can only represent what is
Table 1 Significant SNPs in or near the CCL16 gene on chromosome 17 that met our inclusion criteria with pertinent biological
information implicating them in CCL16 regulation
SNP Base Pair
position
Minor Allele Major Allele MAF Predicted Function RegulomeDB score Meta-analysis p-value
CSF Plasma
rs80329614 34303312 C T 0.1406 downstream 3a 1.666E-19 5.853E-28
rs11080368 34305071 A C 0.1040 intronic No data 2.321E-19 1.777E-27
rs11080369 34305164 C A 0.1042 intronic 1f 2.321E-19 1.777E-27
rs33995560 34303771 C T 0.1122 UTR3 No data 2.941E-19 2.094E-27
rs7216969 34305048 A G 0.1040 intronic 6 2.941E-19 2.094E-27
rs150951362 34304264 A G 0.1008 UTR3 6 1.65E-17 2.05E-20
rs75236781 34306470 C G 0.0613 intronic 6 2.958E-17 3.942E-20
rs149197550 34295254 T C 0.0641 intergenic No data 8.32E-16 9.20E-18
rs4795104 34287400 T A 0.0639 intergenic 6 9.626E-16 1.015E-17
rs4796144 34293003 A G 0.0641 intergenic 6 9.626E-16 1.015E-17
Fig. 1 SNPs located in and around CCL16 are associated with CCL16 protein levels in cerebrospinal fluid (CSF). SNP rs80329614 is the SNP most
strongly associated with CCL16 protein levels in CSF. All significant SNPs are in high linkage disequilibrium, suggesting there is only one
association signal in the region
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currently known based on experimental data. Thus, fur-
ther investigation of this SNP may be warranted. SNP
rs11080369 received a score of “1f”, indicating that it is
known to be part of an eQTL. As such, the rest of the
SNPs are likely part of the same eQTL since they are all
in strong linkage disequilibrium.
Two of the remaining SNPs (rs33995560 and
rs150951362) are located in the 3’UTR of CCL16, which
can play an important role in gene transcription and
translation [23–25], while three others (rs11080368,
rs7216969, rs75236781) are located within CCL16 in-
trons, which can also affect gene regulation [25]. The
remaining three SNPs (rs149197550, rs4795104, and
rs4796144) are located between approximately 8000 and
16000 nucleotides downstream of the gene. Intergenic
variants are generally less likely to affect transcription
than variants within the promoter region or the gene it-
self, though it is possible if the variant affects transcrip-
tion factor binding. Many genes have enhancers both
upstream and downstream that can be active in specific
tissues, depending on the transcription factors expressed
in the tissue [26, 27]. However, given that rs149197550,
rs4795104, and rs4796144 are in high linkage disequi-
librium with the other significant SNPs, we believe
they are less likely to be causal variants. The
remaining three are intergenic. Identifying which
SNP(s) directly affect CCL16 regulation will require
experimental data, but we believe the most suspect
from these 10 is rs80329614 because it has the stron-
gest association, its proximity to the gene, and the
fact that many genes have regulatory elements (e.g.,
enhancers) downstream [26, 27], though the VISTA
enhancer database does not have data on CCL16 en-
hancers [26].
While these 10 SNPs are the most significant and
biologically likely to affect CCL16 regulation based on
our criteria, there may be other SNPs in the individ-
ual CSF and plasma lists that regulate CCL16 inde-
pendently, including those found in other genes.
More biological data will be necessary to identify
causal SNPs. Additionally, our data are not whole ex-
ome or genome and there may be causal variants in
LD with our top hits, associated with the single signal
we’ve seen in our results that were not yet genotyped.
Full sequencing data within the region may reveal
other candidate causal variations.
Conclusions
Our results show that one or more SNPs in or around
the CCL16 gene are associated with increased CCL16
protein levels in both CSF and plasma, but it is not clear
whether that is due to regulation in multiple tissues such
as the brain and liver, or whether the protein is crossing
the blood–brain barrier. Our results are an important
step to resolving this relationship, as they will allow re-
searcher to explore experimentally how these SNPs
affect CCL16 gene regulation in different tissues. Under-
standing CCL16 gene regulation in greater depth will be
important to better understanding its role in human
health.
Fig. 2 SNPs located in and around the CCL16 gene are associated with CCL16 protein levels in blood plasma. As in the CSF analysis, rs80329614
is the SNP most strongly associated with CCL16 protein levels in plasma. All significant SNPs are in high linkage disequilibrium, suggesting there
is only one association signal in the region
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Additional files
Additional file 1: File contains a table of SNPs significantly associated
with CCL16 levels in blood plasma by meta-analysis. (DOCX 88 kb)
Additional file 2: File contains a table of SNPs significantly associated
with CCL16 levels in CSF by meta-analysis. (DOCX 94 kb)
Additional file 3: File contains a Q-Q plot of the CSF data used in this
study. (DOCX 82 kb)
Additional file 4: File contains a Q-Q plot of the plasma data used in
this study. (DOCX 83 kb)
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